Outcomes of Pediatric Liver Transplantation in Glycogen Storage Disease Type 1b—A Single‐Center Experience

Abstract

ABSTRACTBackgroundLiver transplantation (LT) normalizes fasting tolerance in glycogen storage disease type (GSD) 1b. However, reported outcomes post‐LT with respect to correction of neutropenia, infection risk and growth are varied. Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors have been recently shown to improve neutropenia in GSD1b patients.MethodsIn this single‐center retrospective study, we reviewed all children who underwent LT for GSD1b. Neutropenia, dose of granulocyte colony‐stimulating factor (G‐CSF), unplanned hospital attendance, anthropometrics, graft rejection, survival, and the effects of dapagliflozin were analyzed. Data from protocol biopsies obtained at 1, 5, and 10 years post‐LT and immunosuppression levels were collected.ResultsEight children (6 female), all on G‐CSF pre‐transplant, underwent cadaveric LT for GSD1b at median age 3.6 years (IQR 3.3–5.1) with mean follow‐up time of 10.3 years (95% CI 7.5–13.1). Neutrophil count and G‐CSF requirement did not improve post‐LT. Although a reduction in unplanned hospital attendance due to infection (0.98 [95% CI 0.76–1.26] vs. 0.49 [95% CI 0.41 to 0.57] per person‐year, p < 0.01) was observed, gastrointestinal complaints and graft dysfunction accounted for a similar hospitalization burden pre‐ versus post‐LT. Body mass index (BMI) reduced post‐LT (Z‐score 1.47 [95%CI 0.39–2.23] vs. 0.56 [95% CI −0.74 to 1.45], p = 0.02), with no significant change in height.Although all children and grafts have survived, 75% of recipients developed rejection, despite adequate immunosuppression levels, with two children having been found to have developed significant fibrosis on their 5‐year protocol biopsy. Although dapagliflozin allowed cessation of G‐CSF, no improvement in neutrophil count was observed. Despite this, a reduction in gastrointestinal and infection‐related morbidity was noted following dapagliflozin.ConclusionAlthough LT normalizes fasting tolerance in GSD1b and reduces hospital attendance due to infection, morbidity from infection and gastrointestinal manifestations persist. Children in our cohort experienced high rates of rejection necessitating titration of immunosuppression to balance risk of infection against organ rejection. Future studies should investigate whether early introduction of SGLT2 inhibitors post‐LT impact morbidity in this group.